Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up

Satellos Bioscience said the FDA granted Fast Track Designation to SAT-3247 for Duchenne muscular dystrophy. The designation can accelerate development and review of the therapy, a meaningful regulatory step for a clinical-stage biotech. The news is positive for the company but is unlikely to have broad market impact.

Analysis

Satellos Bioscience said the FDA granted Fast Track Designation to SAT-3247 for Duchenne muscular dystrophy. The designation can accelerate development and review of the therapy, a meaningful regulatory step for a clinical-stage biotech. The news is positive for the company but is unlikely to have broad market impact.